Recombinant human lipoprotein lipase/LPL protein, CF

Lieferant: Novus Biologicals

9888-LL-100
NOVU9888-LL-100EA 833 CHF
NOVU9888-LL-100
Recombinant human lipoprotein lipase/LPL protein, CF
Enzyme

Lipo protein lipase (LPL) is a rate-limiting enzyme responsible for the hydrolysis of triglycerides.


LPL forms a non-covalent active homodimeric molecule. Monomeric LPL contains an N-terminal domain with the catalytic triad responsible for lipolysis and a 22-amino acid loop that serves as a cover for the catalytic site in addition to a C-terminal domain that contains the region required for dimerization as well as the primary heparin-binding domain that is important for lipoprotein binding.


LPL is expressed in many tissues where it is synthesized in the ER of parenchymal cells and secreted to capillaries. LPL is highly controlled by regulatory factors such as apolipoproteins, angiopoietins, and hormones. LPL can be produced by macrophages and this expression is a critical event in the pathogenesis of atherosclerosis in addition to contributing to the macrophage inflammatory response.


Variants of LPL have been associated with altered risk of several diseases including coronary heart disease, cerebrovascular accidents and Alzheimer's disease and can result in LPL deficiency and consequent hyperlipidemia . LPL expression is a prognostic marker in B cell chronic lymphocytic leukemia and has been linked to solid tumour cell proliferation. As LPL plays a critical role in several diseases, it is a therapeutic target for both inhibition and induction. The LPL enzyme activity can be inhibited by recombinant mouse ANGPTL3.

Order Now


Learn more

About VWR

Avantor is a vertically integrated, global supplier of discovery-to-delivery solutions for...

Mehr About VWR